Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

Click here to see me place one of these trades LIVE on camera.

D. Keith Grossman net worth and biography

D. Grossman Biography and Net Worth

Director of Outset Medical

Keith has been a leader in the medical technology industry for more than 30 years. He is currently the President and CEO of Nevro Corporation (NVRO). Prior to Nevro, he was named President and CEO of Thoratec Corp (THOR) for the second time in 2014. He led the company’s return to growth, a 2.5x increase in company value and its $3.4 billion acquisition by St. Jude Medical in 2015. He previously served as the CEO, President and Director of Conceptus, Inc. (CPTS) from 2011 to 2013, where he took the company from negative sales growth to over 20% growth, tripled EBIDTA, and led the company’s sale to Bayer Healthcare for over $1.1 billion, a 3x increase in the company’s value prior to his arrival. From 2007 to 2011, He served as Managing Director for TPG Biotech, the $1.1 billion venture capital arm of the private equity firm Texas Pacific Group (TPG). Prior to TPG, he served as CEO, President and Director of Thoratec Corporation from 1996 to 2006, increasing the company’s market value more than 12x, and leading the company from no revenue to more than $200 million in annual revenues. Prior to Thoratec, he held a number of commercial and general management roles with companies including SulzerMedica and American Hospital Supply Corp. He serves as a Director of Vyaire Medical and TherOx, Inc., and he is a former member of the Board of Directors of Intuitive Surgical, Inc. (ISRG), Kyphon, Inc. (KYPH), Zeltiq (which was acquired by Allergan in 2017), and a number of private medical technology companies.

What is D. Keith Grossman's net worth?: The estimated net worth of D. Keith Grossman is at least $10,864.08 as of September 1st, 2021. Mr. Grossman owns 4,584 shares of Outset Medical stock worth more than $10,864 as of April 25th. This net worth evaluation does not reflect any other assets that Mr. Grossman may own. Learn More about D. Keith Grossman's net worth.
How do I contact D. Keith Grossman?: The corporate mailing address for Mr. Grossman and other Outset Medical executives is 3052 ORCHARD DRIVE, SAN JOSE CA, 95134. Outset Medical can also be reached via phone at 669-231-8200 and via email at [email protected]. Learn More on D. Keith Grossman's contact information.
Has D. Keith Grossman been buying or selling shares of Outset Medical?: D. Keith Grossman has not been actively trading shares of Outset Medical during the past quarter. Most recently, D Keith Grossman sold 1,296 shares of the business's stock in a transaction on Wednesday, December 1st. The shares were sold at an average price of $47.92, for a transaction totalling $62,104.32. Learn More on D. Keith Grossman's trading history.
Who are Outset Medical's active insiders?: Outset Medical's insider roster includes Nabeel Ahmed (VP), John Brottem (General Counsel), Rebecca Chambers (CFO), D. Grossman (Director), James Hinrichs (Director), Leslie Trigg (CEO), Martin Vazquez (COO), and Steven Williamson (Insider). Learn More on Outset Medical's active insiders.
Are insiders buying or selling shares of Outset Medical?: In the last year, insiders at the sold shares 34 times. They sold a total of 183,768 shares worth more than $2,821,339.29. The most recent insider tranaction occured on March, 15th when SVP Marc Nash sold 2,391 shares worth more than $5,092.83. Insiders at Outset Medical own 3.5% of the company. Learn More about insider trades at Outset Medical.
Information on this page was last updated on 3/15/2024.

D. Keith Grossman Insider Trading History at Outset Medical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/1/2021	Sell	1,296	$47.92	$62,104.32
11/1/2021	Sell	3,888	$54.77	$212,945.76
10/1/2021	Sell	1,296	$49.69	$64,398.24
9/17/2021	Sell	5,184	$55.00	$285,120.00
9/1/2021	Sell	1,296	$49.17	$63,724.32	4,584
5/3/2021	Sell	2,592	$58.06	$150,491.52	2,592
4/1/2021	Sell	2,592	$55.06	$142,715.52	2,592

D. Keith Grossman Buying and Selling Activity at Outset Medical

Outset Medical Company Overview

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

Today's Range

Now: $2.38

$2.30

$2.47

50 Day Range

MA: $2.56

$1.94

$3.79

2 Week Range

Now: $2.38

$1.92

$24.13

Volume

806,581 shs

Average Volume

1,030,043 shs

Market Capitalization

$123.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99

A new way to collect income from stocks

From DTI | Ad